| Dear Voornaam
Are you a Cancer Research UK-funded postdoc or a postdoc working at one of our centres or institutes? Apply for a place on the Pathway to Independence course to receive support and training to help you transition to an independent position within the next two years.
On this free, hybrid course, youll explore what it means to be an academic group leader, gain insights into what funders are looking for in applications and the steps involved in recruitment. You'll also receive personalised feedback on your research proposal and meet postdocs from research institutions across the UK.
Express your interest by 24 August for a chance to gain the confidence and skills to take the next step in your career. |
|
|---|
|
|---|
|
|
Funding & Research Opportunities |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
| | | Applications accepted all-year round |
|
|---|
|
|---|
|
|
CONGRATULATIONS TO OUR NEWEST GRANT AWARDEES Were excited to announce the latest grant awardees selected by our Discovery Research Committee in the June funding round.
Katrin Ottersbach, Ingo Ringshausen, Simona Parrinello, Christian Siebold, Mark Cragg, Stephen Beers and Ronald Hay received new and renewing Programme Awards, while Christopher Tape was awarded a Programme Foundation Award. Jessica Strid received a Cancer Immunology Project Award and Ran Yan, John Maher, James Arnold and Erik Arstad were awarded Multidisciplinary Project Awards. |
|
|---|
|
|---|
|
|
IAIN FOULKES DISCUSSES DIVERSITY IN RESEARCH Achieving long-term change takes persistence and patience but will ensure that our research workforce is inclusive and diverse, and that our research outputs benefit people equally across the population.
Two years on from publishing our EDI in research action plan Iain Foulkes, our Executive Director of R&I and CEO of Cancer Research Horizons, reflects on the progress were making in an opinion piece for Cancer News. Iain reviews the actions weve taken to improve representation from targeted career support to dedicated funding schemes and events bringing together underrepresented groups and steps to change the nature of research itself. |
|
|---|
|
|---|
|
|
CANCER VACCINE SHOWS PROMISING RESULTS IN PHASE 1 STUDY Our Centre for Drug Development has conducted a first-in-human trial on cancer vaccine candidate, VAC2.
The open label, multi-centre trial determined safety, immunogenicity and survival in patients with advanced non-small cell lung cancer.
Overall, VAC2 developed by Lineage Cell Therapeutics was well-tolerated, with no patients experiencing serious adverse effects and five out of eight patients treated showed immune-related disease stability.
VAC2 uses dendritic cells that have been engineered to present hTERT, a tumour-associated antigen found almost exclusively in cancer cells, to stimulate an immunogenic anti-tumour CD4+/CD8+ T cell response.
|
|
|---|
| JOIN THE ACED SUMMER SCHOOL NEXT MONTH If youre a PhD student or early career researcher, register for this years ACED Summer School to help you address the next steps after discovering a potential biomarker for early detection of cancer.
Hear multi-disciplinary experts discuss the science of validating tests, their clinical utility and study designs for various stages along the translational pathway. Youll also receive science communications training and develop a plan to assess biomarker clinical utility in a group activity.
The summer school will take place online from 48 September.
|
|
|---|
|
|---|
|
|
NK:IO RAISE 1.2M TO ADVANCE PIONEERING NATURAL KILLER CELL THERAPY NK:IO has raised 1.2m in an investment round led by our innovation arm, Cancer Research Horizons.
The company is developing ground-breaking natural killer cell therapies based on a platform that activates blood stem cell progenitors to deliver high natural killer cell tumour-killing potency and cell production.
The platform originated from research by Imperial Colleges Hugh JM Brady and Matt Fuchter, who founded NK:IO with industry executive and entrepreneur Mike Romanos.
The investment will be used to drive NK:IOs cell therapy candidates through full pre-clinical testing. This includes development of a manufacturing process in collaboration with the Cell and Gene Therapy Catapult. |
|
|---|
|
|---|
|
|
HOW CAN LIQUID BIOPSIES BE USED TO DETECT AND TREAT LUNG CANCER? A question Caroline Dive, Director of the Cancer Research UK Cancer Biomarker Centre, discusses in the latest Manchester Cancer Research podcast.
Caroline uses liquid biopsies to measure circulating tumour cells and circulating free tumour DNA to determine targeted therapies and monitor patient response, and she's found that they can also be used to develop models to study the biology of small cell lung cancer.
Hear from Caroline as she shares her research highlights from moving to the new labs at The Christie to discovering the circulating tumour cell patient explant methodology and her work on TRACERx and TRACERx EVO. |
|
|---|
|
|---|
|
|
| | | London, UK & Online 26 September 2023 |
|
|---|
|
|---|
| | | Online 4:00 PM 27 September 2023 |
|
|---|
|
|---|
| | | Paris, France 04 October 2023 |
|
|---|
|
|---|
| | | London, UK 10 October 2023 |
|
|---|
|
|---|
| | | Liverpool, UK 18 October 2023 |
|
|---|
|
|---|
| | | Manchester, UK 03 November 2023 |
|
|---|
|
|---|
| | | London, UK 14 November 2023 |
|
|---|
|
|---|
| | | London, UK 21 November 2023 |
|
|---|
|
|---|
| | | Manchester, UK 27 February 2024 |
|
|---|
|
|---|
|
|
WHAT DID YOU THINK OF THIS EMAIL? We're always looking for ways to improve. Please give us your feedback by clicking below and leaving a comment. |
|
|---|
|
|---|
|
|
| Been forwarded this email?
Subscribe to our newsletter to stay up-to-date. |
|---|
| |
|---|
|
|
|
